Progress in reducing HIV infections has been suboptimal despite availability of effective prevention and treatment interventions and national strategies to bring them to scale. As part of a community-driven process, we expanded previous epidemiologic models using updated surveillance data from the Centers for Disease Control and Prevention to estimate quantitative parameters for ambitious but attainable national HIV prevention goals. We estimated new HIV infections could be reduced by up to 67% and prevalence could begin to decline by 2030 if 95% targets for diagnosis, care retention, and viral suppression are met by 2025 and an additional 20% of transmissions are averted through targeted interventions such as pre-exposure prophylaxis. Notably, this would require the percentage of diagnosed persons retained in HIV care to increase by more than 35 percentage points, which would necessitate innovative models and a substantial expansion of supportive services. Although the HIV incidence reduction goal of 90% as unveiled in the 2019 State of the Union Address is likely unachievable with the current intervention toolkit, it is possible to begin to substantially reduce HIV prevalence in the next decade with sufficient investments and innovation.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Centers for Disease Control and Prevention. HIV Surveill. Report. 2017;2018:29.
Singh S, Song R, Johnson AS, McCray E, Hall HI. HIV incidence, prevalence, and undiagnosed infections in U.S. men who have sex with men. Ann Intern Med. 2018;168(10):685–94.
Shah M, Perry A, Risher K, et al. Effect of the US National HIV/AIDS Strategy targets for improved HIV care engagement: a modelling study. Lancet HIV. 2016;3(3):e140–6.
Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations 2014.
Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018;5(8):e438–47.
Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171–81.
Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.
Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.
Gause NK, Brown JL, Welge J, Northern N. Meta-analyses of HIV prevention interventions targeting improved partner communication: effects on partner communication and condom use frequency outcomes. J Behav Med. 2018;41(4):423–40.
Hergenrather KC, Emmanuel D, Durant S, Rhodes SD. Enhancing HIV prevention among young men who have sex with men: a systematic review of HIV behavioral interventions for young gay and bisexual men. AIDS Educ Prev. 2016;28(3):252–71.
Laisaar KT, Raag M, Rosenthal M, Uuskula A. Behavioral interventions to reduce sexual risk behavior in adults with HIV/AIDS receiving HIV care: a systematic review. AIDS Patient Care STDS. 2015;29(5):288–98.
Perez A, Santamaria EK, Operario D. A systematic review of behavioral interventions to reduce condomless sex and increase HIV testing for Latino MSM. J Immigr Minor Health. 2018;20(5):1261–76.
Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2015;68(3):337–44.
Platt L, Minozzi S, Reed J, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2018;113(3):545–63.
White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States 2010.
White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States: updated to 2020 2015.
Joint United Nations Programme on HIV/AIDS (UNAIDS). Fast-track: ending the AIDS epidemic by 2030. Geneva, Switzerland 2014.
National Alliance of State and Territorial AIDS Directors (NASTAD). Ending the HIV epidemic: jurisdictional plans. 2019; https://www.nastad.org/maps/ending-hiv-epidemic-jurisdictional-plans. Accessed February 10, 2019.
Bradley H, Althoff KN, Buchacz K, et al. Viral suppression among persons in HIV care in the United States during 2009–2013: sampling bias in Medical Monitoring Project surveillance estimates. Ann Epidemiol. 2018. https://doi.org/10.1016/j.annepidem.2018.11.005.
Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2010–2015. 2018.
Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA. 2019. https://doi.org/10.1001/jama.2019.1343.
Bonacci RA, Holtgrave DRUSHIV. Incidence and transmission goals, 2020 and 2025. Am J Prev Med. 2017;53(3):275–81.
Hall HI, Green TA, Wolitski RJ, et al. Estimated future HIV prevalence, incidence, and potential infections averted in the United States: a multiple scenario analysis. J Acquir Immune Defic Syndr. 2010;55(2):271–6.
Skarbinski J, Rosenberg E, Paz-Bailey G, et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med. 2015;175(4):588–96.
Jenness SM, Goodreau SM, Rosenberg E, et al. Impact of the centers for disease control’s HIV preexposure prophylaxis guidelines for men who have sex with men in the United States. J Infect Dis. 2016;214(12):1800–7.
Sullivan PS, Giler RM, Mouhanna F, et al. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017. Ann Epidemiol. 2018;28(12):833–40.
Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol. 2018;28(12):850–7.
Bonacci RA, Holtgrave DR. Simplified estimates of HIV incidence and transmission rates for the USA, 2008-2012. AIDS. 2016;30(2):332–3.
Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data: United States and 6 dependent areas, 2016. HIV Surveill Suppl Rep. 2018;23(4):1065–72.
Siegler AJ, Mouhanna F, Giler RM, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841–9.
Centers for Disease Control and Prevention. Compendium of evidence-based interventions and best practices for HIV prevention: linkage to, retention in, and re-engagement in HIV Care (LRC) Chapter. 2019; https://www.cdc.gov/hiv/research/interventionresearch/compendium/lrc/index.html. Accessed February 11, 2019.
Craw J, Gardner L, Rossman A, et al. Structural factors and best practices in implementing a linkage to HIV care program using the ARTAS model. BMC Health Serv Res. 2010;10:246.
Higa DH, Crepaz N, Mullins MM, Prevention Research Synthesis Project. Identifying best practices for increasing linkage to, retention, and re-engagement in HIV medical care: findings from a systematic review, 1996–2014. AIDS Behav. 2015;24:951–66.
Mizuno Y, Higa DH, Leighton CA, Roland KB, Deluca JB, Koenig LJ. Is HIV patient navigation associated with HIV care continuum outcomes? AIDS. 2018;32(17):2557–71.
Jain KM, Maulsby C, Kinsky S, Charles V, Holtgrave DR, Team PCI. 2015–2020 national HIV/AIDS strategy goals for HIV linkage and retention in care: recommendations from program implementers. Am J Public Health. 2016;106(3):399–401.
Maulsby C, Sacamano P, Jain KM, et al. Barriers and facilitators to the implementation of a national HIV linkage, re-engagement, and retention in care program. AIDS Educ Prev. 2017;29(5):443–56.
Tucker JD, Tso LS, Hall B, et al. Enhancing public health HIV interventions: a qualitative meta-synthesis and systematic review of studies to improve linkage to care, adherence, and retention. EBioMedicine. 2017;17:163–71.
Bradley H, Viall AH, Wortley PM, Dempsey A, Hauck H, Skarbinski J. Ryan white HIV/AIDS program assistance and HIV treatment outcomes. Clin Infect Dis. 2016;62(1):90–8.
Weiser J, Beer L, Frazier EL, et al. Service delivery and patient outcomes in Ryan White HIV/AIDS program-funded and -nonfunded health care facilities in the United States. JAMA Intern Med. 2015;175(10):1650–9.
AIDS United. Ending the HIV epidemic in the United States: a roadmap for federal action 2018.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Bradley, H., Rosenberg, E.S. & Holtgrave, D.R. Data-Driven Goals for Curbing the U.S. HIV Epidemic by 2030. AIDS Behav 23, 557–563 (2019). https://doi.org/10.1007/s10461-019-02442-7
- HIV care continuum
- HIV incidence
- HIV prevalence